Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
ADMS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corp. Plc
2.21%24.551.7%$257.82m
VRXValeant Pharmaceuticals International, Inc.
2.63%28.4814.1%$167.58m
BHCBausch Health Cos., Inc.
2.63%28.480.0%$119.07m
GWPHGW Pharmaceuticals Plc
2.26%108.416.2%$82.69m
MDCOThe Medicines Co.
1.00%52.5020.2%$81.53m
JAZZJazz Pharmaceuticals Plc
3.60%138.642.3%$64.51m
SAGESAGE Therapeutics, Inc.
3.93%146.328.6%$52.92m
PRGOPerrigo Co. Plc
-0.67%49.076.8%$49.70m
ENDPEndo International Plc
-0.66%4.508.8%$45.24m
UTHRUnited Therapeutics Corp.
1.01%90.4314.3%$39.52m
HZNPHorizon Therapeutics Plc
1.51%30.266.6%$38.93m
ICPTIntercept Pharmaceuticals, Inc.
-2.61%80.1016.9%$37.80m
ICLRICON plc
1.42%154.594.2%$37.69m
CTLTCatalent, Inc.
2.65%50.412.4%$31.87m
ARGXargenx SE
1.45%139.370.0%$26.47m

Company Profile

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.